Analyst Price Targets — AVBP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 29, 2026 1:48 pm | — | Truist Financial | $45.00 | $30.16 | TheFly | ArriVent Biopharma assumed with a Buy at Truist |
| December 10, 2025 11:42 am | — | BTIG | $45.00 | $24.91 | TheFly | ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential |
| November 25, 2025 11:23 am | — | Truist Financial | $43.00 | $21.51 | TheFly | ArriVent Biopharma initiated with a Buy at Truist |
| July 10, 2025 9:03 am | Corinne Johnson | Goldman Sachs | $33.00 | $22.03 | TheFly | ArriVent Biopharma resumed with a Buy at Goldman Sachs |
| September 10, 2024 11:49 am | Yigal Nochomovitz | Citigroup | $36.00 | $27.93 | StreetInsider | ArriVent BioPharma (AVBP) PT Raised to $36 at Citi |
| September 10, 2024 6:38 am | Robert Burns | H.C. Wainwright | $36.00 | $28.04 | StreetInsider | ArriVent BioPharma (AVBP) PT Raised to $36 at H.C. Wainwright |
| August 16, 2024 6:39 am | Robert Burns | H.C. Wainwright | $30.00 | $23.62 | StreetInsider | ArriVent BioPharma (AVBP) PT Raised to $30 at H.C. Wainwright |
| July 22, 2024 7:05 am | Jeff Jones | Oppenheimer | $35.00 | $18.77 | StreetInsider | Oppenheimer Starts ArriVent BioPharma (AVBP) at Outperform |
Latest News for AVBP
Management reiterated that the move from early 2026 to mid-2026 was driven by slower event accumulation rather than operational issues, enrollment challenges, or trial redesign. ArriVent ended Q1 with $326.4 million of cash and extended its expected runway from Q3 2027 to Q4 2027, reducing near-term funding risk while supporting late-stage development and commercialization efforts. Shanghai Allist continues to…
NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent Company progress.
NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class…
Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have issued a buy recommendation
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AVBP.
U.S. House Trading
No House trades found for AVBP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.